Logo

Eli Lilly Reports Results of Mirikizumab in P-III (LUCENT-1) Induction Study for the Treatment of Ulcerative Colitis

Share this
Eli Lilly Reports Results of Mirikizumab in P-III (LUCENT-1) Induction Study for the Treatment of Ulcerative Colitis

Eli Lilly Reports Results of Mirikizumab in P-III (LUCENT-1) Induction Study for the Treatment of Ulcerative Colitis

Shots:

  • The P-III LUCENT-1 induction study evaluates mirikizumab vs PBO in 1162 patients with UC who had failed conventional & biologic treatments for 12wks.
  • The results showed that patients achieved the 1EPs of clinical remission (24.2% vs 13.3%), improved symptom relief & resolution, clinical response (63.5% vs 42.2%, symptomatic remission (45.5% vs 27.9%), improvement in symptoms @4wks., reduction in bowel urgency @2wks. & sustained through 12wks.
  • The safety profile was similar to previous studies in UC & consistent with other anti-IL-23p19 Abs. The company plans to submit a BLA to the US FDA for approval of mirikizumab in UC, followed by submissions to other regulatory agencies in H1’22

 Ref: Lilly | Image: Eli Lilly

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions